bionomics-rgb-1024px.png
Bionomics Announces Accepted Abstract and Upcoming Poster Presentations at the American College of Neuropsychopharmacology (ACNP) 2022 Annual Meeting
02 déc. 2022 06h00 HE | Bionomics Ltd
ADELAIDE, Australia, Dec. 02, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX | ASX: BNO) (Bionomics or Company), a clinical-stage biopharmaceutical company developing novel, allosteric ion...
bionomics-rgb-1024px.png
Bionomics Limited Announces Closing of US$5 Million Underwritten Offering of American Depositary Shares in the United States
21 nov. 2022 18h13 HE | Bionomics Ltd
ADELAIDE, Australia, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (ASX: BNO, Nasdaq: BNOX), (“Bionomics” or the “Company”), a clinical-stage biopharmaceutical company developing novel,...
bionomics-rgb-1024px.png
Bionomics Limited Announces Pricing of Underwritten Offering of American Depositary Shares in the United States
16 nov. 2022 18h36 HE | Bionomics Ltd
ADELAIDE, Australia, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (ASX: BNO, Nasdaq: BNOX), (“Bionomics” or the “Company”), a clinical-stage biopharmaceutical company developing novel,...
bionomics-rgb-1024px.png
Bionomics Limited to Participate in Upcoming November Investor Conferences
02 nov. 2022 06h00 HE | Bionomics Ltd
ADELAIDE, Australia, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX | ASX: BNO) (Bionomics or Company), a clinical-stage biopharmaceutical company developing novel, allosteric ion...
bionomics-rgb-1024px.png
Quarterly Activities Report for September 2022
25 oct. 2022 06h00 HE | Bionomics Ltd
ADELAIDE, Australia, Oct. 25, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (ASX: BNO, Nasdaq: BNOX), (Bionomics or the Company) a clinical-stage biopharmaceutical company developing novel, allosteric...
bionomics-rgb-1024px.png
Bionomics Receives R&D Tax Incentive Refund for FY2022 of A$4.6 million
18 oct. 2022 06h00 HE | Bionomics Ltd
ADELAIDE, Australia, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX | ASX: BNO) (Bionomics or Company), a clinical stage biopharmaceutical company, is pleased to announce that the...
bionomics-rgb-1024px.png
Bionomics Limited to Participate in the Cantor Neurology & Psychiatry Conference
04 oct. 2022 06h00 HE | Bionomics Ltd
ADELAIDE, Australia, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX | ASX: BNO) (Bionomics or Company), a clinical-stage biopharmaceutical company developing novel, allosteric ion...
bionomics-rgb-1024px.png
Bionomics to Host KOL Webinar on BNC210 and Social Anxiety Disorder
21 sept. 2022 06h00 HE | Bionomics Ltd
ADELAIDE, Australia, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (ASX:BNO, Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biopharmaceutical company developing novel, allosteric ion...
bionomics-rgb-1024px.png
Bionomics to Participate in Upcoming September Investor Conferences
31 août 2022 06h00 HE | Bionomics Ltd
ADELAIDE, Australia, Aug. 31, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (ASX:BNO Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biopharmaceutical company developing novel, allosteric ion...
bionomics-rgb-1024px.png
Bionomics reports Full Year Financial Results
25 août 2022 06h00 HE | Bionomics Ltd
ADELAIDE, Australia, Aug. 25, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (ASX:BNO, Nasdaq:BNOX), today announced its financial results for the 12 months ended 30 June 2022. Bionomics is a clinical...